Scholarlink

Objective <p>To systematically evaluate the efficacy and safety of proton beam radiotherapy (PBT) compared with photon radiotherapy in the treatment of hepatocellular carcinoma (HCC), thereby providing evidence-based guidance for clinical decision-making in radiotherapy modality selection.</p> Methods <p>A systematic search of PubMed, Web of Science, Cochrane Library, and EMBASE databases was conducted to identify clinical studies comparing PBT with photon radiotherapy for HCC. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated using the GRADE system. Meta-analysis was performed using Review Manager 5.4. The primary outcomes assessed were overall survival (OS), radiation-induced liver injury (RILD), and non-classical RILD.</p> Results <p>Four retrospective cohort studies were included. Meta-analysis results indicated that the PBT group had a hazard ratio for OS of 0.45 (95% CI: 0.34–0.60, <i>P</i> &lt; 0.00001). However, moderate heterogeneity was observed for this outcome (I² = 48%), accompanied by significant publication bias, resulting in a low certainty of evidence. Conversely, PBT significantly reduced the risk of RILD (OR = 0.26, 95% CI: 0.15–0.46, <i>P</i> &lt; 0.00001) and non-classical RILD (OR = 0.27, 95% CI: 0.15–0.47, <i>P</i> &lt; 0.00001). Both outcomes demonstrated no heterogeneity (I² = 0%) and no significant publication bias, yielding a moderate certainty of evidence. The number needed to treat to prevent one case of liver injury was approximately five.</p> Conclusion <p>Compared with photon radiotherapy, PBT offers a clear advantage in reducing the risk of RILD and non-classical RILD in patients with HCC. However, the potential benefit of PBT in improving OS remains inconclusive due to limitations related to study design and publication bias, resulting in a low level of evidence. Clinical selection of radiotherapy modalities should be individualized based on patients’ liver function reserve, tumor characteristics, and medical conditions. Large-scale, multicenter prospective studies are warranted to further validate the long-term survival benefits of PBT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of proton vs. photon radiotherapy for liver cancer: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Hongjie He,
  • Yuanyuan Yan,
  • Yanming Zhang

摘要

Objective

To systematically evaluate the efficacy and safety of proton beam radiotherapy (PBT) compared with photon radiotherapy in the treatment of hepatocellular carcinoma (HCC), thereby providing evidence-based guidance for clinical decision-making in radiotherapy modality selection.

Methods

A systematic search of PubMed, Web of Science, Cochrane Library, and EMBASE databases was conducted to identify clinical studies comparing PBT with photon radiotherapy for HCC. Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and the certainty of evidence was evaluated using the GRADE system. Meta-analysis was performed using Review Manager 5.4. The primary outcomes assessed were overall survival (OS), radiation-induced liver injury (RILD), and non-classical RILD.

Results

Four retrospective cohort studies were included. Meta-analysis results indicated that the PBT group had a hazard ratio for OS of 0.45 (95% CI: 0.34–0.60, P < 0.00001). However, moderate heterogeneity was observed for this outcome (I² = 48%), accompanied by significant publication bias, resulting in a low certainty of evidence. Conversely, PBT significantly reduced the risk of RILD (OR = 0.26, 95% CI: 0.15–0.46, P < 0.00001) and non-classical RILD (OR = 0.27, 95% CI: 0.15–0.47, P < 0.00001). Both outcomes demonstrated no heterogeneity (I² = 0%) and no significant publication bias, yielding a moderate certainty of evidence. The number needed to treat to prevent one case of liver injury was approximately five.

Conclusion

Compared with photon radiotherapy, PBT offers a clear advantage in reducing the risk of RILD and non-classical RILD in patients with HCC. However, the potential benefit of PBT in improving OS remains inconclusive due to limitations related to study design and publication bias, resulting in a low level of evidence. Clinical selection of radiotherapy modalities should be individualized based on patients’ liver function reserve, tumor characteristics, and medical conditions. Large-scale, multicenter prospective studies are warranted to further validate the long-term survival benefits of PBT.